P&G Buys Thorne for $3.8 Billion Amid Rising Demand for Science-Based Supplements

Global consumer goods giant Procter & Gamble (P&G) is expanding its Health Care portfolio after acquiring Thorne for $3.8 billion. This move comes as P&G seeks to capitalize on rising consumer interest in self-care, preventive health, and personalized wellness.

The acquisition of Thorne marks a significant shift in P&G's Health Care business, which has evolved from focusing on traditional oral care and over-the-counter medicines to a broader health and wellness platform. The company's Health Care portfolio already includes well-known brands such as Vicks, Crest, Oral-B, Metamucil, Pepto-Bismol, Fixodent, and Neurobion.

Thorne has built its reputation on scientific rigor, product quality, and a strong relationship with healthcare practitioners. The brand is recommended by tens of thousands of healthcare professionals and used by over seven million consumers, with several products carrying NSF Certified for Sport status.

P&G's acquisition of Thorne reflects the growing demand for science-based supplements and wellness solutions. The global vitamins, minerals, and supplements market is estimated to be worth over $160 billion, driven by consumer interest in preventative health, personalized nutrition, and science-backed wellness solutions.